GSK prepared for potential expansion of meningitis vaccine schedule amid UK outbreak
Amid an ongoing outbreak of meningococcal disease in Kent, England, GSK has said it is ready to work with UK …
Post
-
-
Navigating the valley of death: a how-to from an investor’s perspective
In a crowded biotech landscape full of potential, especially in advanced therapeutic medicinal products (ATMPs), companies must differentiate themselves from …
-
R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia
R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in chronic kidney disease …
-
FDA issues CRL to Aldeyra’s reproxalap drug application
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Aldeyra Therapeutics for its new …
-
Transient but transformative: Sanofi’s mRNA CAR-T enters in vivo race
In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T …
-
Autologous versus allogeneic: how cell therapy development is changing in oncology
Cell therapies have gained steam in oncology since Novartis’s Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR)-T cell therapy …
-
RFK Jr’s vaccine overhaul halted by federal judge’s ruling
US health secretary Robert F Kennedy (RFK) Jr’s ongoing overhaul of the vaccine sector in the US has hit a …
-
FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis
The US Food and Drug Administration (FDA) has accepted for review Sun Pharmaceutical’s supplemental biologics licence application (sBLA) submitted for …
-
Sentynl and PRG partner for Progerinin licence
Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational molecule …
-
Most London patients go private to access weight loss drugs
The majority of patients in London taking weight loss medications are doing so privately, with slow rollouts meaning only a …
-
GSK’s RSV jab secures FDA label expansion to larger adult population
GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug …
-
Widespread US shift from prescription to OTC lies in pharma’s hands
In an interview from February 2026, commissioner of the US Food and Drug Administration (FDA), Marty Makary, said that “everything …
-
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery
Biophytis has expanded its existing partnership with LynxKite Technologies to accelerate AI-driven longevity drug discovery, beginning with the MAS Receptor …
-
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients aged 12 years …
-
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial …
